Cargando…

Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches

Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise t...

Descripción completa

Detalles Bibliográficos
Autores principales: Colmenero Velazquez, Argentina, Iturrieta-Zuazo, Ignacio, Valdivieso Shephard, Juan Luis, Di Natale, Marisa, Rita, Claudia, Ballester González, Rubén, Castañer Alabau, José Luis, Nieto Gañán, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551202/
https://www.ncbi.nlm.nih.gov/pubmed/32764391
http://dx.doi.org/10.3390/antib9030041
_version_ 1783593134626701312
author Colmenero Velazquez, Argentina
Iturrieta-Zuazo, Ignacio
Valdivieso Shephard, Juan Luis
Di Natale, Marisa
Rita, Claudia
Ballester González, Rubén
Castañer Alabau, José Luis
Nieto Gañán, Israel
author_facet Colmenero Velazquez, Argentina
Iturrieta-Zuazo, Ignacio
Valdivieso Shephard, Juan Luis
Di Natale, Marisa
Rita, Claudia
Ballester González, Rubén
Castañer Alabau, José Luis
Nieto Gañán, Israel
author_sort Colmenero Velazquez, Argentina
collection PubMed
description Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise to false positives. In the present study, we tested the use of an anti-rituximab monoclonal antibody (10C5, Abnova) as a method to avoid false positives in FCXM and CDCXM. We used the serum from ten patients who received therapy with rituximab, and the cells were incubated with sera treated or untreated with the 10C5 clone. In previous studies, attempts have been made to control these false positives through the use of pronase, although in these cases the alteration of Human Leukocyte Antigen (HLA) molecules has been found to be a limitation. As an alternative, we performed an assay to exclude false positives by a pre-incubation with anti-rituximab antibody (10C5) in 1:5 proportion avoiding the misinterpretation of crossmatches, particularly in patients with specific donor antibodies (DSA) without affecting the HLA molecules.
format Online
Article
Text
id pubmed-7551202
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75512022020-10-16 Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches Colmenero Velazquez, Argentina Iturrieta-Zuazo, Ignacio Valdivieso Shephard, Juan Luis Di Natale, Marisa Rita, Claudia Ballester González, Rubén Castañer Alabau, José Luis Nieto Gañán, Israel Antibodies (Basel) Case Report Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise to false positives. In the present study, we tested the use of an anti-rituximab monoclonal antibody (10C5, Abnova) as a method to avoid false positives in FCXM and CDCXM. We used the serum from ten patients who received therapy with rituximab, and the cells were incubated with sera treated or untreated with the 10C5 clone. In previous studies, attempts have been made to control these false positives through the use of pronase, although in these cases the alteration of Human Leukocyte Antigen (HLA) molecules has been found to be a limitation. As an alternative, we performed an assay to exclude false positives by a pre-incubation with anti-rituximab antibody (10C5) in 1:5 proportion avoiding the misinterpretation of crossmatches, particularly in patients with specific donor antibodies (DSA) without affecting the HLA molecules. MDPI 2020-08-05 /pmc/articles/PMC7551202/ /pubmed/32764391 http://dx.doi.org/10.3390/antib9030041 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Colmenero Velazquez, Argentina
Iturrieta-Zuazo, Ignacio
Valdivieso Shephard, Juan Luis
Di Natale, Marisa
Rita, Claudia
Ballester González, Rubén
Castañer Alabau, José Luis
Nieto Gañán, Israel
Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title_full Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title_fullStr Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title_full_unstemmed Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title_short Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
title_sort solutions to avoid false positives for rituximab in pre-transplant crossmatches
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551202/
https://www.ncbi.nlm.nih.gov/pubmed/32764391
http://dx.doi.org/10.3390/antib9030041
work_keys_str_mv AT colmenerovelazquezargentina solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT iturrietazuazoignacio solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT valdiviesoshephardjuanluis solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT dinatalemarisa solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT ritaclaudia solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT ballestergonzalezruben solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT castaneralabaujoseluis solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches
AT nietogananisrael solutionstoavoidfalsepositivesforrituximabinpretransplantcrossmatches